Smoking and other determinants of bone turnover

Rolf Jorde¹,² *, Astrid Kamilla Stunes³,⁴, Julia Kubiak¹, Guri Grimnes¹,², Per Medbøe Thorsby⁵, Unni Syversen³,⁶

¹ Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway, ² Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway, ³ Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ⁴ Clinic of Medicine, St. Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway, ⁵ Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Aker Hospital, Oslo, Norway, ⁶ Department of Endocrinology, Clinic of Medicine, St. Olav’s Hospital, Trondheim University Hospital, Trondheim, Norway

* rolf.jorde@unn.no

Abstract

The balance between bone resorption and formation may be assessed by measurement of bone turnover markers (BTMs), like carboxyl-terminal cross-linked telopeptide of type 1 collagen (CTX-1) and procollagen type 1 amino-terminal propeptide (P1NP). Smoking has been shown to influence bone turnover and to reduce bone mass density (BMD), the exact mechanism for this is, however, not settled. In this post-hoc study including 406 subjects (mean age 51.9 years), we aimed to study the impact of smoking on bone turnover. Moreover, we wanted to assess the inter-correlation between substances regulating bone metabolism and BTMs, as well as tracking over time. BMD measurements and serum analyses of CTX-1, P1NP, osteoprotegerin (OPG), receptor activator of nuclear factor κB ligand (RANKL), Dickkopf-1 (DKK1), sclerostin, tumor necrosis factor-α (TNF-α), and leptin were performed. Repeated serum measurements were made in 195 subjects after four months. Adjustments were made for sex, age, body mass index (BMI), smoking status, insulin resistance, serum calcium, parathyroid hormone, 25-hydroxyvitamin D and creatinine. Smokers had higher levels of DKK1 and OPG, and lower levels of RANKL, as reflected in lower BTMs and BMD compared to non-smokers. There were strong and predominantly positive inter-correlations between BTMs and the other substances, and there was a high degree of tracking with Spearman’s rho from 0.72 to 0.92 (P < 0.001) between measurements four months apart. In conclusion, smokers exhibited higher levels of DKK1 and OPG and a lower bone turnover than did non-smokers. The strong inter-correlations between the serum parameters illustrate the coupling between bone resorption and formation and crosstalk between cells.

Introduction

Adult bone undergoes a continuous remodeling with bone resorption by the osteoclasts and bone formation by the osteoblasts, a process that is governed by the osteocytes [1]. The
regulation of bone metabolism is complex, and many signaling pathways are involved [2]. The balance between these processes may be assessed by measurement of bone turnover markers (BTMs) in serum and bone mineral density (BMD) [3]. The recommended BTMs for evaluation of resorption and formation, respectively, are carboxyl-terminal cross-linked telopeptide of type 1 collagen (CTX-1), a degradation product of type 1 collagen bone resorption, and pro-collagen type 1 amino-terminal propeptide (P1NP) [4].

Bone resorption and formation are orchestrated by many substances. Receptor activator of nuclear factor κB ligand (RANKL) promotes osteoclastogenesis and bone resorption [5]. Tumor necrosis factor-α (TNF-α) has an important role in inflammation and stimulates bone resorption in synergy with RANKL [6]. Osteoprotegerin (OPG) is a decoy receptor that binds RANKL and thereby inhibits osteoclast formation [5]. Sclerostin and Dickkopf-1 (DKK1) are potent inhibitors of bone formation via blocking the canonical WNT signaling pathway [7]. The multifunctional adipokine leptin stimulates bone formation by a peripheral pathway and appears to inhibit bone formation through a central pathway as well [8]. Moreover, parathyroid hormone (PTH) and vitamin D are crucial in regulation of serum calcium levels, and also have direct effects on bone [9]. Accordingly, measurements of these substances may yield insight into the mechanisms for alterations in serum levels of BTMs.

Several factors may affect bone homeostasis, including smoking and body mass index (BMI) [10, 11]. Smoking is associated with increased risk for osteoporosis, the exact mechanisms are, however, not settled [12]. We recently performed a vitamin D RCT on cardiovascular risk factors and BTMs in a large group of subjects [13]. Supplementation with vitamin D for four months had minor effects on CTX-1 and P1NP and the other parameters mentioned above [14]. In the present study we did a post-hoc study of this population, addressing the impact of smoking and other factors on bone turnover. Moreover, we examined the intercorrelations between regulators of bone homeostasis and BTMs and their tracking over time.

Methods
Subjects and study design
The design of the study has previously been described in detail [13]. In short, the study was performed in Tromsø, northern Norway (69 degrees north). The subjects were recruited from the population based Tromsø study [15] where 1489 subjects with serum 25-hydroxyvitamin D (25(OH)D) < 42 nmol/L and age < 80 years were invited. 455 subjects came to a screening visit, and 422 subjects were included and randomized to vitamin D versus placebo for four months. Exclusion criteria were granulomatous disease, diabetes, renal stones last five years, or serious diseases that would make the subject unfit for participation, use of vitamin D supplements exceeding 800 IU vitamin D per day, use of solarium on a regular basis, and planned holiday(s) in tropical areas during the intervention period. Women of childbearing potential without use of acceptable contraception (hormonal, IUD) were not included.

All subjects not using anti-resorptive treatment and with successful measurements of BTMs at baseline were included in the cross-sectional BTM analyses, and subjects in the placebo group with successful measurements on both occasions, were included in the tracking analyses.

Measurements
The same measurements were performed at baseline and after four months. Height and weight were measured wearing light clothing and no shoes, and fasting blood samples were drawn. Serum calcium and creatinine, PTH, 25(OH)D, blood glucose, serum insulin and HbA1c and
homeostatic model assessment for insulin resistance (HOMA-IR) were calculated as previously described [13]. BMI was calculated as weight (kg) divide by height (m) squared.

CTX-1 and P1NP were measured by electrochemiluminescence immunoassays with a Cobas e601 kit (Roche Diagnostics, NJ, USA), at the Hormone Laboratory, Oslo University Hospital, Norway. DKK1, leptin, OPG, sclerostin, TNF-α were analyzed using multianalyte profiling Milliplex MAP assay, and RANKL by a single analyte assay (Millipore Corporation, Billerica, MA, USA).

BMD was measured by DXA (GE Lunar Prodigy, Lunar Corporation, Madison, WI, USA) at the hip and lumbar spine, with total hip (mean of left and right, or one side if not both could be measured) and L1 (which had valid measurement in almost every subject) used in the analyses.

Statistical analyses
Normal distribution was evaluated with skewness (between -1 and 1) and kurtosis (between—3 and 3) and visual inspection of histograms and found normal for all dependent parameters except CTX-1, leptin, OPG and sclerostin that attained normal distribution after logarithmic transformation (log10) and used as such in the regression analyses. Where logarithmically transformed the variables are given the prefix "lg.". RANKL was not normally distributed and could not be log transformed and was analyzed with non-parametric statistics. Comparisons between groups at baseline were performed with the Student’s t-test or the Mann-Whitney U test. Correlations were evaluated with partial correlations coefficients with control variables or with Spearman’s rho. Linear regression models were used for evaluation of predictors for the BTMs and the other substances. Sex, age, BMI and smoking status were forced into the model with serum calcium, creatinine, PTH, 25(OH)D and HOMA as potential significant covariates using the stepping method with entry criteria of 0.05 and removal criteria 0.10. Because of the high n, the regression line is indicated in the figures also for non-parametric correlations. There were no observations with extreme leverage.

P < 0.05 (two-tailed) was considered statistically significant. Data are presented as mean ± SD or as median (5, 95 percentile). All statistical analyses were performed using IBM SPSS version 22 software.

Ethics
The study was approved by the Regional Committee for Medical Research Ethics (REK NORD 2013/1464) and by the Norwegian Medicines Agency (2013-003514-40). The study is registered at ClinicalTrials.gov NCT02750293. All subjects gave their written informed consent.

Results
Four-hundred and six subjects had successful measurements of BTMs at baseline and were included in the cross-sectional analyses. Their characteristics are shown in Tables 1 and 2 in relation to gender and smoking status. Males had significantly higher BMD at the total hip, higher serum TNF-α and sclerostin, and significantly lower serum leptin than females. These relations to sex were not dependent on age and were also seen in stratified analyses (age < 45, age 45–55, > 55 years, S1 Table). Smokers had significantly lower BMD at the total hip, lower P1NP, CTX-1 and RANKL, and higher DKK1 and OPG than non-smokers. Smokers also had significantly lower creatinine than non-smokers, a difference that also was significant (P < 0.001) after adjusting for sex, age and BMI.
Determinants of the BTMs and bone regulating substances

In the linear regression model with sex, age, BMI, smoking status, serum calcium, creatinine, PTH, 25(OH)D and HOMA-IR as potential confounders, the above relations between BTMs and bone regulating substances, sex and smoking status were confirmed (Tables 3 and 4). Age was strongly associated with OPG and sclerostin, but not with P1NP or CTX-1. The age-OPG and age-sclerostin relations were seen in both genders, for OPG only in those above 50 years of age, and for sclerostin in subjects both above and below 50 years of age (S2 Table).

BMI was negatively associated with CTX-1, and positively associated with the bone formation inhibitor DKK1. Serum creatinine was positively associated to CTX-1 and sclerostin, whereas PTH and serum calcium showed only few weak associations. Remarkably, there were no significant associations between 25(OH)D and the BTMs or bone regulating substances in the linear regression model. Furthermore, there were significant relations for HOMA-IR with leptin and OPG (Tables 3 and 4).

Except for leptin, where the regression model had an adjusted R² of 0.666, the other regression models only explained 4–23% of the variance of the BTMs or bone regulating substances. In particular, the R² for P1NP and CTX-1 were 0.035 and 0.118, respectively. Inclusion of the bone regulating substances DKK1, leptin, TNF-α, OPG, sclerostin and RANKL as co-variates in the model increased the R² to 0.062 and 0.149 for P1NP and CTX-1, respectively.

Table 1. Characteristics of the subjects at baseline and in relation to gender.

|                      | All subjects (n = 406) | Males (n = 212) | Females (n = 194) | Mean difference (95% CI) | P-value* |
|----------------------|------------------------|-----------------|------------------|--------------------------|----------|
| Males/females        | 212/194                |                 |                  |                          |          |
| Current smokers/non-smokers | 86/320              | 47/165          | 39/155           | -0.4 (-2.1, 1.3)         | 0.644    |
| Age (years)          | 51.9 ± 8.7             | 52.0 ± 9.0      | 51.6 ± 8.3       | -0.6 (-1.6, 0.3)         | 0.191    |
| BMI (kg/m²)          | 27.8 ± 4.9             | 28.1 ± 4.6      | 27.4 ± 5.3       | -0.02 (-0.03, -0.01)     | 0.008    |
| Serum calcium (mmol/L) | 2.27 ± 0.07           | 2.26 ± 0.007    | 2.26 ± 0.08      | -0.138 (-15.8, -11.8)    | <0.001   |
| Serum creatinine (μmol/L) | 71.3 ± 12.4         | 77.9 ± 11.6     | 64.1 ± 8.6       | -13.8 (-15.8, -11.8)     | <0.001   |
| Serum PTH (pmol/L)   | 6.7 ± 2.0              | 6.6 ± 1.9       | 6.9 ± 2.2        | -0.3 (-0.1, 0.7)         | 0.115    |
| Serum 25(OH)D (nmol/L) | 34.0 ± 12.9           | 33.9 ± 13.2     | 34.1 ± 12.5      | 0.2 (-2.3, 2.7)          | 0.862    |
| HbA1c (%)            | 5.49 ± 0.31            | 5.15 ± 0.33     | 5.47 ± 0.29      | -0.04 (-0.10, 0.03)      | 0.257    |
| HOMA-IR              | 2.72 (0.94, 8.28)      | 3.38 (1.08, 11.84) | 2.14 (0.84, 6.32) |                        | 0.000    |
| Serum P1NP (pg/ml)   | 44.8 ± 15.1            | 44.5 ± 13.7     | 45.2 ± 16.6      | 0.7 (-2.2, 3.7)          | 0.625    |
| Serum CTX-1 (pg/ml)  | 0.34 (0.18, 0.62)      | 0.36 (0.19, 0.67) | 0.35 (0.16, 0.59) |                        | 0.207    |
| Serum DKK1 (pg/ml)   | 1456 ± 396             | 1461 ± 402      | 1451 ± 392       | -10 (-87, 68)            | 0.808    |
| Serum Leptin (pg/ml) | 11081 (1725, 53375)    | 7488 (1212, 30290) | 20094 (3051, 68867) |                        | <0.001   |
| Serum TNF-α (pg/ml)  | 2.40 ± 0.81            | 2.58 ± 0.82     | 2.20 ± 0.76      | -0.38 (-0.53, -0.22)     | <0.001   |
| Serum OPG (pg/ml)    | 306 (192, 479)         | 306 (188, 498)  | 306 (208, 460)   |                        | 0.979    |
| Serum sclerostin (pg/ml) | 1806 (1030, 3140)    | 2044 (1126, 3286) | 1642 (998, 2764)  |                        | <0.001   |
| Serum RANKL (pg/ml)  | 0.0 (0.0, 46.8)        | 0.0 (0.0, 55.8) | 0.0 (0.0, 24.9) |                        | 0.002    |
| BMD total hip (g/cm²)** | 0.993 ± 0.133         | 1.032 ± 0.118   | 0.950 ± 0.136    | -0.081 (-0.109, -0.054)  | 0.000    |
| BMD L1 (g/cm²)**     | 1.067 ± 0.156          | 1.084 ± 0.159   | 1.048 ± 0.152    | -0.036 (-0.070, -0.003)  | 0.035    |

* Females vs males (Chi-square test, student’s t-test or Mann-Whitney U test)
** 334 subjects (177 males, 157 females; 265 non-smokers, 69 smokers)

Data shown as mean ± SD or median (5, 95 percentile)

https://doi.org/10.1371/journal.pone.0225539.t001
Correlations between the BTMs

In the analyses with partial correlations controlling for sex, age, BMI, smoking status, serum calcium, creatinine, PTH, 25(OH)D and HOMA-IR, there was a strong positive correlation between P1NP and CTX-1 ($r = 0.67$, $P < 0.001$) (Fig 1), and also several significant associations.

Table 2. Characteristics of the subjects at baseline in relation to smoking status.

|                         | Non-smokers (n = 320) | Smokers (n = 86) | Mean difference (95% CI) | P-value* |
|-------------------------|-----------------------|------------------|--------------------------|----------|
| Males/females           | 165/155               | 47/39            |                          | 0.629    |
| Age (years)             | 51.6 ± 8.6            | 52.7 ± 8.7       | -1.0 (-3.1, 1.0)         | 0.326    |
| BMI (kg/m²)             | 28.0 ± 4.9            | 27.1 ± 4.8       | 0.8 (-0.3, 2.0)          | 0.156    |
| Serum calcium (mmol/L)  | 2.27 ± 0.07           | 2.28 ± 0.08      | -0.01 (-0.03, 0.01)      | 0.329    |
| Serum creatinine (μmol/L)| 72.7 ± 12.1          | 66.2 ± 12.0      | 6.5 (3.6, 9.4)           | <0.001   |
| Serum PTH (pmol/L)      | 6.9 ± 2.0             | 6.2 ± 2.0        | 0.7 (0.2, 1.2)           | 0.005    |
| Serum 25(OH)D (nmol/L)  | 34.8 ± 13.0           | 31.0 ± 12.0      | 3.8 (0.7, 6.8)           | 0.013    |
| HbA1c (%)               | 5.46 ± 0.31           | 5.61 ± 0.30      | -0.16 (-0.23, -0.08)     | <0.001   |
| HOMA-IR                 | 2.79 (0.96, 8.36)     | 2.62 (0.80, 7.30) |                        | 0.191    |
| Serum P1NP (pg/ml)      | 45.8 ± 15.5           | 41.1 ± 12.9      | 4.7 (1.1, 8.3)           | 0.010    |
| Serum CTX-1 (pg/ml)     | 0.36 (0.19, 0.63)     | 0.31 (0.17, 0.56) |                        | 0.006    |
| Serum DKK1 (pg/ml)      | 1435 ± 391            | 1537 ± 410       | -102 (-196, -8)          | 0.034    |
| Serum Leptin (pg/ml)    | 11189 (1796, 59548)   | 9328 (1320, 37599) |                      | 0.051    |
| Serum TNF-α (pg/ml)     | 2.39 ± 0.81           | 2.45 ± 0.83      | -0.06 (-0.26, 0.13)     | 0.520    |
| Serum OPG (pg/ml)       | 303 (191, 459)        | 325 (208, 525)   |                          | 0.020    |
| Serum sclerostin (pg/ml)| 1852 (1016, 3140)    | 1768 (1126, 2936) |                      | 0.895    |
| Serum RANKL (pg/ml)     | 0.0 (0.0, 50.3)       | 0.0 (0.0, 22.1)  |                          | 0.046    |
| BMD total hip (g/cm²)** | 1.001 ± 0.136         | 0.964 ± 0.119    | 0.037 (0.002, 0.073)    | 0.037    |
| BMD L1 (g/cm²)**        | 1.073 ± 0.150         | 1.041 ± 0.178    | 0.032 (-0.009, 0.074)   | 0.129    |

*Non-smokers vs smokers (Chi-square test, student’s t-test or Mann-Whitney U test)

**334 subjects (177 males, 157 females; 265 non-smokers, 69 smokers)

Data shown as mean ± SD or median (5, 95 percentile)

https://doi.org/10.1371/journal.pone.0225539.t002

Correlations between the BTMs

In the analyses with partial correlations controlling for sex, age, BMI, smoking status, serum calcium, creatinine, PTH, 25(OH)D and HOMA-IR, there was a strong positive correlation between P1NP and CTX-1 ($r = 0.67$, $P < 0.001$) (Fig 1), and also several significant associations.

Table 3. Beta coefficients with 95% confidence intervals from linear regression models for bone turnover markers with sex, age, BMI and smoking status as variables forced into the model, and with serum calcium, creatinine, PTH, 25(OH)D and HOMA as potential significant covariates in the 406 subjects.

|                         | P1NP | Lg. CTX-1 | DKK1 | Lg. Leptin |
|-------------------------|------|----------|------|-----------|
| Sex*                    | -0.432 (-3.363, 2.499) | 0.772 | -0.006 (-0.045, 0.033) | 0.764 | -14.37 (-90.42, 61.68) | 0.711 | -0.478 (-0.534, -0.423) | <0.001 |
| Age (years)             | 0.132 (-0.038, 0.301) | 0.127 | 0.001 (0.000, 0.003) | 0.126 | -4.587 (-8.953, -0.221) | 0.040 | -0.001 (-0.004, 0.002) | 0.435 |
| BMI (kg/m²)             | -0.327 (-0.627, -0.026) | 0.033 | -0.008 (-0.011, -0.004) | <0.001 | 16.03 (8.302, 23.75) | <0.001 | 0.050 (0.043, 0.057) | <0.001 |
| Smoking status**        | -5.092 (-8.675, -1.509) | 0.005 | -0.044 (-0.085, -0.004) | 0.032 | 114.8 (22.55, 207.0) | 0.015 | -0.029–0.093, 0.036 | 0.379 |
| Serum creatinine (μmol/L)| 0.003 (0.001, 0.004) | 0.022 | 0.019 (0.006, 0.033) | 0.005 |
| Serum PTH (pmol/L)      | 0.010 (0.002, 0.018) | 0.020 | 653.5 (132.6, 1174) | 0.014 |
| Serum calcium (mmol/L)  | 0.264 (0.041, 0.486) | 0.020 | 653.5 (132.6, 1174) | 0.014 |
| Serum 25(OH)D (nmol/L)  | 0.034 (0.021, 0.046) | 0.005 |
| HOMA-IR                 | 0.379 |
| Adjusted R²             | 0.035 | 0.134 | 0.075 | 0.672 |

*Males = 1. females = 0;

**smokers = 1. non-smokers = 0

https://doi.org/10.1371/journal.pone.0225539.t003
in-between the bone regulating substances. All of these associations were positive, except for a weak negative association between sclerostin and CTX-1 (Tables 5 and 6).

There were significant negative correlations between P1NP and CTX-1 versus BMD both at the total hip and L1, shown for P1NP and total hip in Fig 2. For the other bone regulating substances, the only significant association with BMD was a positive correlation with sclerostin (Tables 5 and 6, Fig 3).

![Fig 1. Relation between the serum CTX-1 and P1NP in the 406 subjects.](https://doi.org/10.1371/journal.pone.0225539.g001)
One hundred and ninety-five subjects in the placebo group completed the four months intervention, had successful BTM measurements at baseline and end of study, and were included in the tracking analyses. Except for RANKL, there was a high degree of tracking from baseline to end of study, with correlation coefficient rho ranging from 0.72 to 0.92 (Figs 4 and 5). These correlations were considerably higher than the corresponding ones for serum calcium, PTH and 25(OH)D (Table 7).

Table 5. Partial correlation coefficients for bone turnover markers with sex, age, BMI, smoking status, serum calcium, creatinine, PTH, 25(OH)D and HOMA as control variables in the 406 subjects.

|                                | P1NP          | Lg. CTX-1      | DKK1         | Lg. Leptin     |
|--------------------------------|---------------|----------------|--------------|---------------|
|                                | Partial       | Partial        | Partial      | Partial       |
|                                | correlation   | correlation    | correlation  | coefficient   |
| Serum P1NP (pg/ml)             | 0.655         | <0.001         | 0.014        | 0.774         |
| Lg. serum CTX-1 (pg/ml)        | 0.014         | 0.774          | 0.001        | 0.982         |
| Serum DKK1 (pg/ml)             | -0.012        | 0.813          | -0.043       | 0.395         |
| Lg. serum Leptin (pg/ml)       | 0.104         | 0.040          | 0.147        | 0.003         |
| Serum TNF-α (pg/ml)            | 0.012         | 0.774          | 0.001        | 0.982         |
| Lg. serum OPG (pg/ml)          | 0.102         | 0.043          | -0.017       | 0.735         |
| Lg. serum sclerostin (pg/ml)   | -0.084        | 0.095          | -0.120       | 0.017         |
| BMD total hip (g/cm²)          | -0.208        | <0.001         | -0.224       | <0.001        |
| BMD L1 (g/cm²)*                | -0.116        | 0.038          | -0.143       | 0.010         |

* n = 334

https://doi.org/10.1371/journal.pone.0225539.t005

**Tracking**

One hundred and ninety-five subjects in the placebo group completed the four months intervention, had successful BTM measurements at baseline and end of study, and were included in the tracking analyses. Except for RANKL, there was a high degree of tracking from baseline to end of study, with correlation coefficient rho ranging from 0.72 to 0.92 (Figs 4 and 5). These correlations were considerably higher than the corresponding ones for serum calcium, PTH and 25(OH)D (Table 7).

Table 6. Partial correlation coefficients for bone turnover markers with sex, age, BMI, smoking status, serum calcium, creatinine, PTH, 25(OH)D and HOMA as control variables in the 406 subjects.

|                                | TNF-α         | Lg. OPG        | Lg. sclerostin | RANKL         |
|--------------------------------|---------------|----------------|----------------|---------------|
|                                | Partial       | Partial        | Partial        | Spearman’s    |
|                                | correlation   | correlation    | coefficient    | rho coefficient|
| Serum P1NP (pg/ml)             | 0.104         | 0.040          | 0.102          | 0.095         |
| Lg. serum CTX-1 (pg/ml)        | 0.147         | 0.003          | -0.017         | 0.017         |
| Serum DKK1 (pg/ml)             | 0.237         | <0.001         | -0.017         | 0.001         |
| Lg. serum Leptin (pg/ml)       | 0.150         | 0.003          | -0.017         | 0.001         |
| Serum TNF-α (pg/ml)            | 0.150         | 0.003          | 0.207          | 0.154         |
| Lg. serum OPG (pg/ml)          | 0.207         | <0.001         | 0.207          | 0.002         |
| Lg. serum sclerostin (pg/ml)   | 0.154         | 0.002          | 0.287          | <0.001        |
| BMD total hip (g/cm²)*         | -0.026        | 0.643          | 0.003          | 0.003         |
| BMD L1 (g/cm²)*                | 0.019         | 0.738          | 0.084          | 0.134         |

* n = 334

https://doi.org/10.1371/journal.pone.0225539.t006
Fig 2. Relation between P1PN and BMD total hip in the 406 subjects.

https://doi.org/10.1371/journal.pone.0225539.g002

Fig 3. Relation between sclerostin and BMD total hip in the 406 subjects.

https://doi.org/10.1371/journal.pone.0225539.g003
Fig 4. Relation between serum CTX-1 at baseline and after four months in the 195 subjects in the placebo group in the intervention study.

https://doi.org/10.1371/journal.pone.0225539.g004

Fig 5. Relation between serum P1NP at baseline and after four months in the 195 subjects in the placebo group in the intervention study.

https://doi.org/10.1371/journal.pone.0225539.g005
The present study provides novel insight into the mechanisms for the smoking-induced bone loss. Smokers exhibited higher levels of DKK1, reflected in lower level of the bone formation marker P1NP compared to non-smokers. Moreover, OPG, RANKL and PTH levels were lower in smokers, as mirrored in the attenuated level of the bone resorption marker CTX-1. Accordingly, the inferior BMD in smokers may be attributed to a lower bone turnover. To our knowledge, this is the first study to demonstrate enhanced levels of DKK1 and OPG in smokers. A positive correlation was observed between sclerostin levels and BMD. Accordingly, smokers displayed lower sclerostin levels than non-smokers, however, not significant. BMI was negatively related with the BTMs, and positively associated with leptin.

In line with previous studies, we observed lower BMD in smokers compared to non-smokers [12]. This complies with the higher DKK1 levels in smokers causing inhibition of bone formation, as reflected in lower P1NP levels. Sclerostin, another inhibitor of bone formation, tended to be reduced among smokers, reflecting the lower BMD. Our findings concerning the positive relation between circulating sclerostin and BMD support observations in other populations [16] and could be attributed to a larger pool of osteocytes in those with high BMD. In accordance with a study by Reseland et al. [17], the smokers displayed lower leptin levels, although not significant, that could contribute to impairment of bone formation.

Bone resorption assessed by CTX-1 was also lower in smokers, which concords with lower levels of RANKL and higher levels of OPG. These findings support most studies [12], with the exception of OPG showing decreased or equal levels compared to non-smokers. The reason for this discrepancy is unclear. It should be kept in mind that circulating OPG may be derived from other sources than bone [18]. In line with several studies, PTH levels were attenuated among smokers, in spite of lower 25(OH)D levels than in non-smokers [19]. The lower PTH levels could contribute to the decline in RANKL and increase in OPG.

Our data indicate that the bone impairment in smokers may be attributed to a lower bone turnover state. Low bone turnover is also observed in patients with type 2 diabetes [20] where a significant increase in fracture risk is seen, in spite of normal or high BMD [21]. Correspondingly, a meta-analysis by Kanis et al. reported an increase in fracture risk among smokers that was substantially greater than that explained by measurement of BMD [22]. Thus, in a low

Table 7. Spearman’s correlation coefficient rho between serum values at baseline and end of study in the 195 subjects in the placebo group in the intervention study.

| Bone turnover marker | Rho between baseline and end of study value | P-value |
|----------------------|--------------------------------------------|---------|
| Serum P1NP           | 0.821                                      | <0.001  |
| Serum CTX-1          | 0.819                                      | <0.001  |
| Serum DKK1           | 0.860                                      | <0.001  |
| Serum Leptin         | 0.919                                      | <0.001  |
| Serum TNF-α          | 0.715                                      | <0.001  |
| Serum OPG            | 0.781                                      | <0.001  |
| Serum sclerostin     | 0.834                                      | <0.001  |
| Serum RANKL          | 0.465                                      | <0.001  |
| Serum calcium        | 0.614                                      | <0.001  |
| Serum creatinine     | 0.925                                      | <0.001  |
| Serum PTH            | 0.714                                      | <0.001  |
| Serum 25(OH)D        | 0.453                                      | <0.001  |
| HOMA-IR              | 0.760                                      | <0.001  |

https://doi.org/10.1371/journal.pone.0225539.t007

Discussion

The present study provides novel insight into the mechanisms for the smoking-induced bone loss. Smokers exhibited higher levels of DKK1, reflected in lower level of the bone formation marker P1NP compared to non-smokers. Moreover, OPG, RANKL and PTH levels were lower in smokers, as mirrored in the attenuated level of the bone resorption marker CTX-1. Accordingly, the inferior BMD in smokers may be attributed to a lower bone turnover. To our knowledge, this is the first study to demonstrate enhanced levels of DKK1 and OPG in smokers. A positive correlation was observed between sclerostin levels and BMD. Accordingly, smokers displayed lower sclerostin levels than non-smokers, however, not significant. BMI was negatively related with the BTMs, and positively associated with leptin.

In line with previous studies, we observed lower BMD in smokers compared to non-smokers [12]. This complies with the higher DKK1 levels in smokers causing inhibition of bone formation, as reflected in lower P1NP levels. Sclerostin, another inhibitor of bone formation, tended to be reduced among smokers, reflecting the lower BMD. Our findings concerning the positive relation between circulating sclerostin and BMD support observations in other populations [16] and could be attributed to a larger pool of osteocytes in those with high BMD. In accordance with a study by Reseland et al. [17], the smokers displayed lower leptin levels, although not significant, that could contribute to impairment of bone formation.

Bone resorption assessed by CTX-1 was also lower in smokers, which concords with lower levels of RANKL and higher levels of OPG. These findings support most studies [12], with the exception of OPG showing decreased or equal levels compared to non-smokers. The reason for this discrepancy is unclear. It should be kept in mind that circulating OPG may be derived from other sources than bone [18]. In line with several studies, PTH levels were attenuated among smokers, in spite of lower 25(OH)D levels than in non-smokers [19]. The lower PTH levels could contribute to the decline in RANKL and increase in OPG.

Our data indicate that the bone impairment in smokers may be attributed to a lower bone turnover state. Low bone turnover is also observed in patients with type 2 diabetes [20] where a significant increase in fracture risk is seen, in spite of normal or high BMD [21]. Correspondingly, a meta-analysis by Kanis et al. reported an increase in fracture risk among smokers that was substantially greater than that explained by measurement of BMD [22]. Thus, in a low
bone turnover state, impairment of bone quality seems to be proportionally more pronounced than the decline in BMD [23].

The pathophysiological mechanisms by which smoking may affect bone are multiple. Smoking induces alterations in calciotropic hormones, has an impact on the pituitary-adrenal axis and sex hormones, has pronounced inflammatory effects and induces oxidative stress [12]. Tobacco smoke contains more than 7000 substances that could contribute to the skeletal effects. The most abundant agent nicotine has been shown to affect both bone formation and resorption. Nicotine inhibits osteogenesis directly through binding to nicotinic acetylcholine receptors on osteoblasts and indirectly by inducing a rise in ACTH and cortisol levels [24]. Excess cortisol inhibits bone formation, and this may be mediated by DKK1 as glucocorticoids have been shown to stimulate DKK1 in vitro [25]. This complies with the enhanced levels of DKK1 among smokers in the present study. Nicotine has also been shown to suppress formation of osteoclasts with large nuclei and reduce the area of resorption, compatible with a suppression of bone resorption [26].

Other constituents of tobacco smoke that may be negative for the skeleton are polycyclic aryl hydrocarbon compounds which have been shown to exert antioestrogenic effects [27]. Whether this occurs via stimulation of DKK1 remains to be explored. One of these substances, benzo[a]pyrene (BaP), which is present in high concentrations in cigarette smoke, has been found to inhibit osteoclast differentiation and bone resorption, probably attributed to a crosstalk between the aryl hydrocarbon receptor and RANKL signaling pathways [28].

Tobacco smoke also contains many heavy metals including cadmium and lead of which bone is one of the main targets [29]. Both cadmium and lead exposure have been observed to inhibit osteoblast differentiation and to increase bone resorption, and are associated with low BMD and increased fracture risk [30]. Exposure of these metals are also shown to affect the calciotropic hormones by reducing vitamin D and PTH levels [30, 31]. A decline in magnesium levels has been reported in subjects exposed to cadmium [31], and in smokers compared with controls [32]. Hypomagnesemia may thus contribute to the lower PTH levels observed in smokers.

Taken together, the different components of tobacco smoke seem to induce effects on both bone formation and resorption that are predominantly inhibitory, resulting in a lower bone turnover than in non-smokers. Our findings are in support of these data and give some additional insight into mechanisms for bone impairment in smokers.

We observed lower serum creatinine in smokers compared to non-smokers as also shown in previous studies [33]. This could be attributed to lower muscle mass among smokers, as demonstrated in several studies [34]. Unfortunately, we do not have data on muscle mass in our study population. The attenuated creatinine could also be ascribed to hyperfiltration as elaborated on by Halimi et al. [35].

The negative associations between P1NP and CTX-1 and BMI are consistent with a decline in bone turnover with increasing weight. This concords with the low bone turnover reported in individuals with metabolic syndrome and type 2 diabetes [36]. Altered adipokine secretion and insulin resistance are some of the factors suggested to explain this relationship [11]. We did, however, not find any relation between insulin resistance, as evaluated by HOMA-IR, and BMD or the formation/resorption markers P1NP and CTX-1. On the other hand, significant correlations were revealed between HOMA-IR and OPG and RANKL. This is in line with previous studies showing a relation between OPG and insulin resistance [37, 38], as well as between RANKL and insulin resistance [39]. In this regard, it should be recalled that these substances are not only produced in bone, as the cardiovascular system and the immune system being the main sources of OPG and RANKL [18], respectively. As shown previously, leptin and TNF-α were also highly correlated with HOMA-IR [40, 41]. Our findings underscore the
The interplay between the skeleton and energy metabolism, exemplified by in vitro studies showing interaction between insulin and osteoblasts [42], as well as proliferation of pancreatic β-cells by osteocalcin stimulation [43].

The effect of sex on leptin, TNF-α and sclerostin levels was unrelated to age both in linear regression and in age-stratified analyses, in accordance with other studies [44–46]. The association between sex and leptin was strongly modified after correction for BMI and might have been further reduced if data on fat mass had been available and included in the analyses [47]. Similarly, the strong relations between age and sclerostin and OPG have been reported before [44–46, 48, 49].

As anticipated, there were strong inter-correlations between the substances regulating bone metabolism and the BTMs. This was particularly seen between CTX-1 and P1NP, demonstrating the coupling between bone resorption and formation [6]. Furthermore, almost all correlations between the other substances and BTMs, regardless of assumed effect being promoting or inhibiting bone formation, were positive. This again illustrates the cross-talk between the bone cells.

Tracking is a result of both natural biological variation over time, which includes circadian variation [50] and meal responses [51], as well as assay reproducibility [52]. There is a high degree of tracking for BMD [53] and it was therefore reasonable to assume that this was the case for the bone-active substances and BTMs, which was also found. To our knowledge there are only a few reports on tracking of individual bone related substances [54, 55], but none where these substances and the BTMs are evaluated together. This high degree of tracking makes it likely that our cross-sectional results are valid for bone metabolism over time and not only represent findings from a single measurement.

Our study has several weaknesses. Unfortunately, RANKL levels were below the detection level in a substantial number of the participants, as also reported by others [56–58]. Non-measurable levels were observed primarily in smokers, reflecting the low RANKL levels in this group. We had no information on physical activity and intake of calcium and magnesium, which could affect the bone turnover as well as the BMD [44]. The study was observational, and no conclusions about causality can be drawn. We included mainly subjects with low serum 25(OH)D levels, and although they otherwise were healthy, our results may not be applicable to subjects with vitamin D sufficiency. However, except for RANKL, we found no relations between serum 25(OH)D and the BTMs and bone-related substances, and inclusion of 25(OH)D in the regression model did not affect the results. Furthermore, the regression model only explained less than 15% of the variance of P1NP and CTX-1, even after inclusion of the bone regulating substances in the model. On the other hand, our study has strengths as we included a large group of subjects and measured both BTMs and several other bone regulating substances.

In conclusion, our study gives novel insight into mechanisms for the smoking-induced osteoporosis. The strong inter-correlations between the serum parameters illustrate the coupling between bone resorption and formation and crosstalk between cells. Moreover, the high degree of tracking illustrates the validity of our data.

Supporting information

S1 Table. Supplementary Table 1. Serum leptin, TNF-α, sclerostin and BMD total hip in relation to age and gender.

S2 Table. Supplementary Table 2. Standardized beta coefficients from linear regression models for lg. OPG and lg. sclerostin in relation to sex and age group with sex, age, BMI,
smoking status, serum calcium, creatinine, PTH, 25(OH)D and HOMA as covariates in the 406 subjects.

(SAV)

S1 Data. The study’s underlying data set.

(Acknowledgments)

The study was supported by grants from the North Norway Regional Health Authorities (grant number SFP1277-16), UiT The Arctic University of Norway, and the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology.

The superb assistance from the staff at the Clinical Research Unit (and in particular Bjørg Skog Hegset and Britt-Ann Winther Eilertsen) and the Department of Medical Biochemistry at the University Hospital of North Norway is gratefully acknowledged.

Author Contributions

Conceptualization: Rolf Jorde, Julia Kubiak, Guri Grimnes.

Data curation: Rolf Jorde.

Formal analysis: Rolf Jorde, Astrid Kamilla Stunes, Per Medbøe Thorsby, Unni Syversen.

Funding acquisition: Rolf Jorde, Julia Kubiak.

Methodology: Rolf Jorde.

Project administration: Rolf Jorde.

Resources: Rolf Jorde, Guri Grimnes.

Writing – original draft: Rolf Jorde.

Writing – review & editing: Rolf Jorde, Astrid Kamilla Stunes, Julia Kubiak, Guri Grimnes, Per Medbøe Thorsby, Unni Syversen.

References

1. Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy. 2005; 4:325–8. https://doi.org/10.2174/1568010054022015 PMID: 16101541

2. Ikeda K, Takeshita S. Factors and mechanisms involved in the coupling from bone resorption to formation: how osteoclasts talk to osteoblasts. J Bone Metab. 2014; A21(3):163–7.

3. Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA. DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful? Eur J Endocrinol. 2018; 178:R19–R31. https://doi.org/10.1530/EJE-17-0585 PMID: 29046326

4. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Gamero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22:391–420. https://doi.org/10.1007/s00198-010-1501-1 PMID: 21184054

5. Martin TJ, Sims NA. RANKL/OPG; Critical role in bone physiology. Rev Endocr Metab Disord. 2015; 16:131–9. https://doi.org/10.1007/s11154-014-0308-6 PMID: 25557611

6. Zhao B. TNF and Bone Remodeling. Curr Osteoporos Rep. 2017; 15:126–34. https://doi.org/10.1007/s11914-017-0358-z PMID: 28477234

7. Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017; 96:29–37. https://doi.org/10.1016/j.bone.2016.10.007 PMID: 27742498
8. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, et al. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001; 16:1426–33. https://doi.org/10.1359/jbmr.2001.16.8.1426 PMID: 11499865

9. Goltzman D. Functions of vitamin D in bone. Histochem Cell Biol. 2018; 149:305–12. https://doi.org/10.1007/s00418-018-1648-y PMID: 29435763

10. Yoon V, Maalouf NM, Sakhaae K. The effects of smoking on bone metabolism. Osteoporos Int. 2012; 23:2081–92. https://doi.org/10.1007/s00198-012-1940-y PMID: 22349964

11. Viljakainen H, Ivaska KK, Paldinius P, Lipsanen-Nyman M, Saukkonen T, Pietilainen KH, et al. Suppressed bone turnover in obesity: a link to energy metabolism? A case-control study. J Clin Endocrinol Metab. 2014; 99:2155–63. https://doi.org/10.1210/jc.2013-3097 PMID: 24606073

12. Al-Bashaireh AM, Haddad LG, Weaver M, Chengguo X, Kelly DL, Yoon S. The Effect of Tobacco Smoking on Bone Mass: An overview of Pathophysiological Mechanisms. J Osteoporos. 2018; 2018:1206235. https://doi.org/10.1155/2018/1206235 PMID: 30631414

13. Kubiak J, Kamycheva E, Jorde R. Vitamin D supplementation does not improve CVD risk factors in vitamin D-insufficient subjects. Endocr Connect. 2018; 7:840–9. https://doi.org/10.1530/EC-18-0144 PMID: 29764903

14. Jorde R, Stunes AK, Kubiak J, Joakimsen R, Grimnes G, Thorsby PM, et al. Effects of vitamin D supplementation on bone turnover markers and other bone-related substances in subjects with vitamin D deficiency. Bone. 2019; 124:7–13. https://doi.org/10.1016/j.bone.2019.04.002 PMID: 30591898

15. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njølstad I. Cohort profile: the Tromso Study. Int J Epidemiol. 2012; 41:961–7. https://doi.org/10.1093/ije/dyr049 PMID: 21422063

16. Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, et al. Sclerostin is positively associated with bone mineral density in men and women and negatively associated with carotid calcified atherosclerotic plaque in men from the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2014; 99:315–21. https://doi.org/10.1210/jc.2013-3168 PMID: 24178795

17. Reseland JE, Mundal HH, Hollung K, Haugen F, Zahid N, Andresen SA, et al. Cigarette smoking may reduce plasma leptin concentration via catecholamines. Prostaglandins Leukot Essent Fatty Acids. 2005; 73:43–9. https://doi.org/10.1016/j.plefa.2005.04.006 PMID: 15964536

18. Secchiero P, Coralli F, Pandolfi A, Consoli A, Candido R, Fabris B, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol. 2006; 169:2236–44. https://doi.org/10.2353/ajpath.2006.060398 PMID: 17148684

19. Fujiyoshi A, Polgreen LE, Gross MD, Reis JP, Sidney S, Jacobs DR Jr. Smoking habits and parathyroid hormone concentrations in young adults: The CARDIA study. Bone Rep. 2016; 5:104–9. https://doi.org/10.1016/j.bonr.2016.04.003 PMID: 27795978

20. Khan TS, Fraser LA. Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype. J Osteoporos. 2015; 2015:174186. https://doi.org/10.1155/2015/174186 PMID: 25874154

21. Compston J. Type 2 diabetes mellitus and bone. J Intern Med. 2018; 283:140–53. https://doi.org/10.1111/joim.12725 PMID: 29265670

22. Canis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005; 16:155–62. https://doi.org/10.1007/s00198-004-1640-3 PMID: 15175845

23. Farr JN, Drake MT, Amin S, Melton LJ 3rd, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014; 29:787–95. https://doi.org/10.1002/jbmr.2106 PMID: 24123088

24. Steptoe A, Ussher M. Smoking, cortisol and nicotine. Int J Psychophysiol. 2006; 59:228–35. https://doi.org/10.1016/j.ijpsycho.2005.10.011 PMID: 16337291

25. Komori T. Glucocorticoid Signaling and Bone Biology. Horm Metab Res. 2016; 48:55–63. https://doi.org/10.1055/s-0044-110571 PMID: 27871116

26. Tanaka H, Tanabe N, Kawato T, Nakai K, Kariya T, Matsumoto S, et al. Nicotine affects bone resorption and suppresses the expression of cathepsin K, MMP-9 and vacuolar-type H(+) -ATPase d2 and actin organization in osteoclasts. PLoS One. 2013; 8:e59402. https://doi.org/10.1371/journal.pone.0059402 PMID: 23550529

27. Yun C, Weiner JA, Chun DS, Yun J, Cook RW, Schallmo MS, et al. Mechanistic insight into the effects of Aryl Hydrocarbon Receptor activation on osteogenic differentiation. Bone Rep. 2017; 6:51–9. https://doi.org/10.1016/j.bonr.2017.02.003 PMID: 28377982

28. Voronov I, Li K, Tenenbaum HC, Manolson MF. Benzo[a]pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-kappaB. Biochem Pharmacol. 2008; 75:2034–44. https://doi.org/10.1016/j.bcp.2008.02.025 PMID: 18396263
29. Caruso RV, O’Connor RJ, Stephens WE, Cummings KM, Fong GT. Toxic metal concentrations in cigarettes obtained from U.S. smokers in 2009: results from the International Tobacco Control (ITC) United States survey cohort. Int J Environ Res Public Health. 2013; 11:202–17. https://doi.org/10.3390/ijerph11010020 PMID: 24452255

30. Rodríguez J, Mandalunis PM. A Review of Metal Exposure and Its Effects on Bone Health. J Toxicol. 2018; 2018:4854152. https://doi.org/10.1155/2018/4854152 PMID: 30675155

31. Ibrahim KS, Beshir S, Shaisy EM, Shaheen W. Effect of Occupational Cadmium Exposure on Parathyroid Gland. Open Access Maced J Med Sci. 2016; 4:302–6. https://doi.org/10.3889/oamjms.2016.042 PMID: 27335606

32. Kotlinska-Hasiec E, Makara-Studzinska M, Czajkowski M, Rzecki Z, Olszewski K, Stadnik A, et al. Plasma magnesium concentrations in patients undergoing coronary artery bypass grafting. Ann Agric Environ Med. 2017; 24:181–4. https://doi.org/10.5604/12321966.1232767 PMID: 2866490

33. Jorde R, Saleh F, Figenschau Y, Kamycha E, Haug E, Sundsfjord J. Serum parathyroid hormone (PTH) levels in smokers and non-smokers. The fifth Tromsø study. Eur J Endocrinol. 2005; 152:39–45. https://doi.org/10.1530/eje.1.01816 PMID: 15762185

34. Degens H, Gayan-Ramirez G, van Hees HW. Smoking-induced skeletal muscle dysfunction: from evidence to mechanisms. Am J Respir Crit Care Med. 2015; 191:620–5. https://doi.org/10.1164/rccm.201410-1830PP PMID: 25581779

35. Halimi JM, Giraudreau B, Vol S, Cacèes E, Nivet H, Lebranchu Y, et al. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000; 58:1285–92. https://doi.org/10.1046/j.1523-1755.2000.00284.x PMID: 10972692

36. Holloway-Kew KL, De Abreu LLF, Kotowicz MA, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and insulin resistance. Clin Endocrinol. 2000; 53:411–5. https://doi.org/10.1046/j.1365-2261.2000.01712.x PMID: 10970603

37. Duan P, Yang M, Wei M, Liu J, Tu P. Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes. Int J Endocrinol. 2017; 2017:8724869. https://doi.org/10.1155/2017/8724869 PMID: 28255300

38. Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Boezau A, et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013; 19:358–63. https://doi.org/10.1038/nm.3084 PMID: 23936210

39. Zuo H, Shi Z, Yuan B, Dai Y, Wu G, Hussain A. Association between serum leptin concentrations and insulin resistance: a population-based study from China. PLoS One. 2013; 8:e54615. https://doi.org/10.1371/journal.pone.0054615 PMID: 23499440

40. Miyazaki Y, Pipek R, Mandarino LJ, DeFronzo RA. Tumor necrosis factor alpha and insulin resistance in obese type 2 diabetic patients. Int J Obes Relat Metab Disord. 2003; 27:88–94. https://doi.org/10.1038/sj.ijo.0802187 PMID: 12532159

41. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010; 142:296–308. https://doi.org/10.1016/j.cell.2010.06.003 PMID: 20655470

42. Wetzel G, Kafai MR, McCarth y E. Serum leptin concentrations are not related to dietary patterns but are related to sex, age, body mass index, serum triacylglycerol, serum insulin, and plasma glucose in the US population. Nutr Metab. 2009; 6:3.

43. Baumgartner RN, Ross RR, Waters DL, Brooks WM, Morley JE, Montoya GD, et al. Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes. Obes Res. 1999; 7:141–9. https://doi.org/10.1002/(SICI)1050-8528.1999.tb00695.x PMID: 10102250

44. Altinova AE, Toruner F, Akturk M, Bukan N, Yetkin I, Cakir N, et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand J Clin Lab Invest. 2011; 71:340–3. https://doi.org/10.3109/00365513.2011.570868 PMID: 21486111
49. Shinkov AD, Borissova AM, Kovatcheva RD, Atanassova IB, Vlahov JD, Dakovska LN. Age and menopausal status affect osteoprotgerin and osteocalcin levels in women differently, irrespective of thyroid function. Clin Med Insights Endocrinol Diabetes. 2014; 7:19–24. https://doi.org/10.4137/CME. S1546 PMID: 25125991

50. Redmond J, Fulford AJ, Jarjou L, Zhou B, Prentice A, Schoenmakers I. Diurnal Rhythms of Bone Turnover Markers in Three Ethnic Groups. J Clin Endocrinol Metab. 2016; 101:3222–30. https://doi.org/10.1210/jc.2016-1183 PMID: 27294326

51. Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C. Mechanism of circadian variation in bone resorption. Bone. 2002; 30:307–13. https://doi.org/10.1016/s8756-3282 (01)00662-7 PMID: 11792602

52. Jorde R, Sneve M, Hutchinson M, Emans N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol. 2010; 171:903–8. https://doi.org/10.1093/aje/kwq005 PMID: 20219763

53. Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, Hangartner TN, et al. Tracking of bone mass and density during childhood and adolescence. J Clin Endocrinol Metab. 2010; 95:1690–8. https://doi.org/10.1210/jc.2009-2319 PMID: 20194709

54. Gruszfeld D, Kulaga Z, Wierzbicka A, Rzehak P, Grote V, Martin F, et al. Leptin and Adiponectin Serum Levels from Infancy to School Age: Factors Influencing Tracking. Child Obes. 2016; 12:179–87. https://doi.org/10.1089/chi.2015.0245 PMID: 27027910

55. Li LJ, Rifas-Shiman SL, Aris IM, Mantzoros C, Hivert MF, Oken E. Leptin trajectories from birth to mid-childhood and cardio-metabolic health in early adolescence. Metabolism. 2019; 91:30–8. https://doi.org/10.1016/j.metabol.2018.11.003 PMID: 30412696

56. Chang MC, Chen YJ, Lian YC, Chang BE, Huang CC, Huang WL, et al. Butyrate Stimulates Histone H3 Acetylation, 8-Isoprostane Production, RANKL Expression, and Regulated Osteoprotegerin Expression/Secretion in MG-63 Osteoblastic Cells. Int J Mol Sci. 2018; 19:4071.

57. Mohamed HG, Idris SB, Mustafa M, Ahmed MF, Åström AN, Mustafa K, et al. Influence of Type 2 Diabetes on Prevalence of Key Periodontal Pathogens, Salivary Matrix Metalloproteinases, and Bone Remodeling Markers in Sudanese Adults with and without Chronic Periodontitis. Int J Dent. 2016; 2016:6296854. https://doi.org/10.1155/2016/6296854 PMID: 26989414

58. Bauer S, Hofbauer LC, Rauner M, Strzelczyk A, Kellinghaus C, Hallmeyer-Eilgner S, et al. Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)—a prospective multicenter study. Epilepsy Res. 2013; 106:417–22. https://doi.org/10.1016/j.eplepsyres.2013.06.020 PMID: 23916144